Stephen Bruso

Stephen Bruso joined the Morningside investment team in 2019 and focuses on investments in both the
biopharma and digital health fields. He has extensive experience providing operational and management
oversight to early-stage companies. Mr. Bruso serves as a director for numerous private companies
including Cognito Therapeutics, Kuzani Pharmaceuticals, Curai, Suvera, Vesigen Therapeutics,
Neuroelectrics, Innodem Neurosciences, Manistee Therapeutics and DeepCure; he is a board observer
at Linus Health.
Prior to joining Morningside, Mr. Bruso worked at a series of molecular diagnostics startups spun out
from the Church Lab at HMS before co-leading the development and launch of cloud software products
in the e-commerce space. He received his MBA from Boston University in 2019, graduating magna cum
laude. He received his BA from Emory University in 2009.